Glucophage SR is a sustained release formulation of metformin designed to improve glycemic control in patients with type 2 diabetes. It functions by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity. The drug is absorbed gradually along the gastrointestinal tract leading to a prolonged reduction in postprandial glucose excursions. Metformin primarily inhibits hepatic gluconeogenesis through activation of amp activated protein kinase. It also modulates intestinal glucose absorption and alters the composition of gastrointestinal microbiota to support its therapeutic effect. The sustained release matrix ensures steady plasma concentrations providing consistent pharmacodynamic activity over an extended period.

Glucophage SR is the sustained release formulation of metformin used to lower blood glucose in patients with type 2 diabetes. It belongs to the class of biguanide antihyperglycemic agents that improve glycemic control by reducing hepatic glucose production. The drug increases insulin sensitivity in peripheral tissues such as skeletal muscle and adipose tissue. By inhibiting hepatic gluconeogenesis it decreases the amount of glucose released into the bloodstream. Metformin also enhances peripheral glucose uptake through activation of amp-activated protein kinase pathways which promote cellular glucose utilization. The sustained release coating allows a gradual delivery of the active ingredient leading to steadier plasma concentrations over time. This pharmacokinetic profile supports consistent therapeutic effect while minimizing rapid fluctuations in blood sugar levels.

Glucophage SR may cause gastrointestinal discomfort such as nausea and diarrhea. Some patients experience a metallic taste or mild abdominal pain. Rarely, low blood sugar can occur, especially when combined with other diabetes medications. Skin reactions like rash or itching have been reported in occasional cases. Elevated liver enzymes are seldom observed and usually detected through routine blood tests. Swelling of the ankles or sudden weight gain should prompt a medical review.

Glucophage SR may cause gastrointestinal discomfort such as nausea and diarrhea. It can also lead to a metallic taste in the mouth. Some users experience dizziness or lightheadedness, especially when standing up quickly. Skin reactions like rash or itching are possible but less common. Changes in taste perception sometimes occur. Rarely, it may result in low blood sugar levels if combined with other glucose-lowering medications. Fatigue and headache are among the reported symptoms.